Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business Updates
- Positive Data from the Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia Presented at European Hematology Association Meeting 2022 - - Positive Data from the Ongoing Phase 2 Study... | August 12, 2022